Regulatory Submission Delays: 12 Root Causes and Proven Prevention Tactics (FDA & Health Canada)
This guide identifies 12 causes of FDA and Health Canada submission delays—like incomplete data and poor eCTD discipline—and offers tactics…
Post-Approval Compliance, Step by Step: A Practical Roadmap for US and Canadian Markets
This guide outlines essential post-approval compliance for US and Canadian markets, covering renewals, vigilance reporting, QMS, inspection readiness, and effective…
How Strategic Regulatory Consulting Accelerates International Market Expansion
Strategic regulatory consulting accelerates international market entry by ensuring compliance with US FDA and Health Canada, minimizing risks, optimizing resources,…
2026 FDA and Health Canada Updates: Practical Impacts for Natural Health Products—and How to Prepare
In 2026, FDA and Health Canada will enforce stricter regulations on natural health products, including labeling, submissions, site licensing, GMP…
How to Navigate Multi-Market Regulatory Submissions with Confidence and Precision
Streamline multi-market regulatory submissions by harmonizing dossiers, managing timelines, and leveraging expert consultancy like Arora 297 to reduce duplication, risks,…
Cosmetic Ingredient Compliance: Proven Strategies for a Fast-Changing Global Rulebook
This guide outlines strategies for global cosmetic ingredient compliance, emphasizing regulatory understanding, ingredient safety, monitoring banned substances, proper notifications, labeling,…
Key Elements of an Effective QMS for Medical Device Manufacturers in North America
Effective medical device QMS ensures compliance with ISO 13485, FDA QMSR, and Health Canada's MDSAP through documented processes, risk management,…
Custom Compliance Roadmaps for Diverse Product Portfolios in the US and Canada
This document outlines creating tailored regulatory roadmaps for US FDA and Health Canada compliance across diverse product portfolios, emphasizing strategic…
Beyond Approval: Enhancing Post-Approval Regulatory Support to Sustain Product Viability and Market Competitiveness
Post-approval regulatory support via a risk-based lifecycle plan ensures product viability and competitiveness by meeting FDA and Health Canada requirements.…
Regulatory Intelligence in Pharma: Anticipate Change, De‑Risk Compliance, and Accelerate Approvals
Regulatory intelligence enables pharma firms to anticipate regulatory changes, reduce compliance risks, and optimize IND, NDA, ANDA submissions in the…
